3-{4-[2-(benzoxazol-2-ylmethylamino)ethoxy]phenyl}-2-ethoxypropionic acid | 1026578-37-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-{4-[2-(benzoxazol-2-ylmethylamino)ethoxy]phenyl}-2-ethoxypropionic acid
• 英文别名: 3-[4-[2-(1,3-Benzoxazol-2-ylmethylamino)ethoxy]phenyl]-2-ethoxypropanoic acid
• CAS: 1026578-37-9
• 化学式: C₂₁H₂₄N₂O₅
• 分子量: 384.432
• InChiKey: AIXADAPTHFUGCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  93.8
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Biaromatic ligand activators of PPARgamma receptors
  申请人：——

  公开号：US20030134885A1

  公开（公告）日：2003-07-17

  Novel pharmaceutical/cosmetic compositions contain at least one biaromatic ligand activator of a PPAR&ggr; receptor, such biaromatic ligand having the structural formula (I): 1 and are well suited, inter alia, for regulating and/or restoring skin lipid metabolism, for treating a wide variety of dermatological afflictions, and for preventing and/or treating the signs of aging and/or dry skin.

  新型的制药/化妆品组合物至少包含一种PPAR&ggr;受体的双芳香配体激活剂，该双芳香配体具有结构式(I):1，并且非常适合调节和/或恢复皮肤脂质代谢，治疗各种皮肤病症，以及预防和/或治疗衰老和/或干燥皮肤的迹象。
• COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME
  申请人：Cohen Stephen Michael

  公开号：US20140227289A1

  公开（公告）日：2014-08-14

  The present invention relates to a method of treating or preventing insulin resistance syndrome in an animal body by administering an inhibitor of protein kinase RNA-like endoplasmic reticulum kinase (PERK) gene, or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof or a method of reducing activity of transcription factors of the FOXO family (Foxo 1, 3a, 4 and 6) by administering an inhibitor of protein kinase RNA-like endoplasmic reticulum kinase (PERK) gene, or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof. The present invention also relates to different compounds and methods for using PERK gene or PERK protein.

  本发明涉及通过给动物体内注射蛋白激酶RNA样内质网激酶（PERK）基因的抑制剂或其功能变体，或PERK蛋白或其功能变体的抑制剂，或通过给动物体内注射蛋白激酶RNA样内质网激酶（PERK）基因的抑制剂或其功能变体，或PERK蛋白或其功能变体的抑制剂来减少FOXO家族转录因子（Foxo 1、3a、4和6）活性的方法，用于治疗或预防动物体内的胰岛素抵抗综合征。本发明还涉及不同的化合物和使用PERK基因或PERK蛋白的方法。
• Biaromatic ligand activators of PPARGAMMA receptors
  申请人：Bernardon Jean-Michel

  公开号：US20070043046A1

  公开（公告）日：2007-02-22

  Novel pharmaceutical/cosmetic compositions contain at least one biaromatic ligand activator of a PPARγ receptor, such biaromatic ligand having the structural formula (I): and are well suited, inter alia, for regulating and/or restoring skin lipid metabolism, for treating a wide variety of dermatological afflictions, and for preventing and/or treating the signs of aging and/or dry skin.

  新型药物/化妆品组合物包含至少一种PPARγ受体的双芳香基配体激活剂，该双芳香基配体具有结构式（I）并且非常适合调节和/或恢复皮肤脂质代谢，用于治疗各种皮肤病症和预防和/或治疗衰老和/或干燥皮肤的迹象。
• Proliferation- and differentiation-modulating agents and uses therefor
  申请人：Saunders Andrew Nicholas

  公开号：US20050245473A1

  公开（公告）日：2005-11-03

  The present invention discloses the use of E2F pathway modulators and optionally a differentiation stimulus in methods for treating or preventing conditions associated with the deregulation of epithelial cell proliferation and differentiation and for diagnosing the presence or risk of developing such conditions.

  本发明公开了在治疗或预防与上皮细胞增殖和分化失调有关的病症以及诊断是否存在或有发生此类病症风险的方法中使用 E2F 通路调节剂和分化刺激物的方法。
• UTILISATION D'ACTIVATEURS DE PPAR-GAMMA POUR TRAITER DES DESORDRES CUTANES
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：EP1041977B1

  公开（公告）日：2008-07-30